Skip to content

Cutaneous lymphoma study

Role of IL-9 and Th9 cell in T Cell Lymphoma with cutaneous involvement - CTCL Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2017/04/008356
Enrollment
30
Registered
2017-04-17
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C847- Anaplastic large cell lymphoma, ALK-negative Health Condition 2: C846- Anaplastic large cell lymphoma, ALK-positive Health Condition 3: C84A- Cutaneous T-cell lymphoma, unspecified Health Condition 4: C840- Mycosis fungoides Health Condition 5: C844- Peripheral T-cell lymphoma, not classified Health Condition 6: null- T Cell Lymphoma

Interventions

None listed

Sponsors

IIT Mumbai
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adults aged equal to or above 18 years Mature T cell lymphoma with cutaneous involvement Treatment na�¯ve except those who have received only topical steroids Written informed consent

Exclusion criteria

Exclusion criteria: HIV positive patients Co-existent psoriasis or autoimmune disorders Patients on Immunosuppressive therapy

Design outcomes

Primary

MeasureTime frame
Proportion of patients with elevated IL-9 level at baseline will be estimated. 2. TH9 cell percentage in skin biopsy at baseline will be estimated. Timepoint: Day 0

Secondary

MeasureTime frame
Change in the IL-9 levels at completion of therapy or at 6 months whichever is earlier. 4. Correlation of baseline IL-9 level TH9 cells with disease stage and response status. Timepoint: IL-9 level at 6 months, Correlation of basline IL-9 level and TH9 cells with best response.

Countries

India

Contacts

Public ContactDr Hasmukh Jain

TATA MEMEORIAL HOSPITAL

dr.hkjain@gmail.com02224177018

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026